Biogen Reports 8% YOY Sales Growth in Q1 2025, Driven by Rare Disease Therapies
According to Biogen Inc.’s (NASDAQ: BIIB) Q1 2025 report released this week, the US firm...
Zhongsheng Pharma’s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose...
Alchemab Therapeutics Licenses ATLX-1282 to Eli Lilly for ALS Treatment
UK-based biotech Alchemab Therapeutics Ltd entered into a licensing agreement with US major Eli Lilly...
China’s NMPA Releases Draft Guidelines for Development Risk Management Plan
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released the...
AstraZeneca’s Calquence Gains EU Approval for Mantle Cell Lymphoma
UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) announced receiving another indication approval in the European...
Huadong Medicine’s HDM2005 Receives NMPA Approval for DLBCL Clinical Trial
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...
Fresenius Medical Care Reports 1% Revenue Growth in Q1 2025
Germany-based Fresenius Medical Care (FRA: FMEA) released its 2025 Q1 financial report, showing total revenues...
Innovent Biologics Completes First Dosing in Phase II Study for Efdamrofusp Alfa in DME
China-based Innovent Biologics, Inc. (HKG: 1801) announced the completion of the first patient dosing in...
EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology
EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series...
Beijing Wantai’s HIV Urine Self-Test Kit Gains WHO Prequalification
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced that its HIV urine...
Formosa Pharmaceuticals Licenses Clobetasol Propionate to Apotex for Mexico
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with Apotex Inc., granting the...
Shuangcheng Pharma’s Generic Bivalirudin Approved by Australia’s TGA
China-based Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) announced that the market filing for its...
Everest Medicines’ Nefecon Receives Full Approval from NMPA for IgAN Treatment
China-based Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has converted...
Novartis to Acquire Regulus Therapeutics for Up to $1.7 Billion
Swiss pharmaceutical giant Novartis (NYSE: NVS) is set to acquire U.S.-based Regulus Therapeutics Inc. (NASDAQ:...
CSPC’s JMT202 Receives FDA IND Approval for Hypertriglyceridemia Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has secured an investigational new drug (IND) approval...
Guilin Sanjin’s BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials
Guilin Sanjin Pharmaceutical Co., Ltd. (SHE: 002275) announced that its Shanghai-based subsidiary Dragon Boat Biopharmaceutical’s...
Innovent Biologics Presents Positive IBI302 Results for nAMD at ARVO 2025
China-based Innovent Biologics, Inc. (HKG: 1801) announced the presentation of 1-year results from its Phase...
AccurEdit Therapeutics’ ART001 Shows Promising Results in ATTR Treatment
China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd. has published the latest data...
Novo Nordisk’s Once-Daily Wegovy NDA Accepted for FDA Review
Denmark-based Novo Nordisk (NYSE: NVO) announced that its New Drug Application (NDA) filing for its...
Nanjing Perlove Medical Equipment Files IPO Application in Hong Kong
China-based Nanjing Perlove Medical Equipment Co., Ltd., a specialist in medical imaging and surgical robotics,...